Drug Therapy

  • SGLT-2 inhibitors: A new era in managing diabetic kidney disease starts now
    Jonathan J. Taliercio, DO, George Thomas, MD, Georges N. Nakhoul, MD, MEd, Tushar J. Vachharajani, MD and Ali Mehdi, MD, MEd
    Cleveland Clinic Journal of Medicine January 2021, 88 (1) 59-63; DOI: https://doi.org/10.3949/ccjm.88a.20190

    Randomized controlled trials of these new agents had positive outcomes.

  • 2020: A year like no other
    Brian F. Mandell, MD, PhD
    Cleveland Clinic Journal of Medicine December 2020, 87 (12) 710-711; DOI: https://doi.org/10.3949/ccjm.87b.12020

    Veracity and bias are issues we address on a daily basis.

  • In Reply: COVID-19 coagulopathy
    Simon R. Mucha, MD, Siddharth Dugar, MD, Keith McCrae, MD, Douglas Joseph, DO, John Bartholomew, MD, Gretchen L. Sacha, PharmD, RPh, BCCCP and Michael Militello, PharmD, RPh, BCPS
    Cleveland Clinic Journal of Medicine December 2020, 87 (12) 712; DOI: https://doi.org/10.3949/cjm.87c.12002

    An attempt to balance the potential risks and benefits of intensified prophylaxis.

  • COVID-19 coagulopathy
    Anup Katyal, MD
    Cleveland Clinic Journal of Medicine December 2020, 87 (12) 712; DOI: https://doi.org/10.3949/ccjm.87c.12001

    Skepticism of high-intensity prophylaxis for patients with D-dimer ≥ 3.0 µg/mL.

  • Dexamethasone or hydrocortisone in COVID-19?
    Chia Siang Kow and Syed Shahzad Hasan
    Cleveland Clinic Journal of Medicine December 2020, 87 (12) 715; DOI: https://doi.org/10.3949/ccjm.87c.12005

    Dexamethasone should be favored over hydrocortisone.

  • Fever in a lung transplant recipient
    Graham Walter, MD, Hanna Lyubetska, MD, MSc and Aditya Sharma, MD, FRCPC
    Cleveland Clinic Journal of Medicine December 2020, 87 (12) 735-741; DOI: https://doi.org/10.3949/ccjm.87a.19132

    A 36-year-old woman presents with high fevers, chills, nausea, decreased oral intake, and diarrhea.

  • Double the reasons for giving the flu vaccine in 2020
    Brian F. Mandell, MD, PhD
    Cleveland Clinic Journal of Medicine November 2020, 87 (11) 647-648; DOI: https://doi.org/10.3949/ccjm.87b.11020

    Limiting the impact of other diseases, possibly including COVID-19.

  • Does my healthy 65-year-old patient still need the 13-valent pneumococcal conjugate vaccine (PCV13)?
    Craig D. Nielsen, MD, FACP and Xian Wen Jin, MD, PhD, FACP
    Cleveland Clinic Journal of Medicine November 2020, 87 (11) 656-658; DOI: https://doi.org/10.3949/ccjm.87a.20012

    The short answer is no—but it is not that simple.

  • Convalescent plasma for COVID-19: Promising, not proven
    Simon R. Mucha, MD and NurJehan Quraishy, MD
    Cleveland Clinic Journal of Medicine November 2020, 87 (11) 664-670; DOI: https://doi.org/10.3949/ccjm.87a.ccc056

    The evidence is suggestive but weak. Trials are ongoing.

  • The effect of disease-modifying antirheumatic drugs on vaccine immunogenicity in adults
    Alvin Lee Day, MD, Kevin L. Winthrop, MD, MPH and Jeffrey R. Curtis, MD, MS, MPH
    Cleveland Clinic Journal of Medicine November 2020, 87 (11) 695-703; DOI: https://doi.org/10.3949/ccjm.87a.20056

    Patients can have variable responses to vaccines, depending on the vaccine and the DMARD.

Pages